Improving early breast cancer treatment: the role of granulocyte colony-stimulating factor
Breast cancer is still the leading cause of death in patients with malignant tumors. Among women with breast cancer, standard combination chemotherapy with anthracyclines and taxanes reduces mortality from this disease by about one third compared to patients not receiving chemotherapy and is the sta...
Guardado en:
Autores principales: | Inna P. Ganshina, Kristina A. Ivanova, Elena V. Lubennikova, Alexandr V. Arkhipov, Liudmila G. Zhukova |
---|---|
Formato: | article |
Lenguaje: | RU |
Publicado: |
IP Habib O.N.
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/5f4e68188d1b418fb57bc9b19ae96a98 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Clinical Outcomes of Secondary Prophylactic Granulocyte Colony-Stimulating Factors in Breast Cancer Patients at a Risk of Neutropenia with Doxorubicin and Cyclophosphamide-Based Chemotherapy
por: Jae Hee Choi, et al.
Publicado: (2021) -
Reduction of febrile neutropenia by using long-acting granulocyte colony-stimulating factors in patients with solid tumors receiving every-2-week chemotherapy
por: I. B. Kononenko, et al.
Publicado: (2020) -
Evaluating the Prognostic Role of Monocytopenia in Chemotherapy-Induced Febrile Neutropenia Patients Treated with Granulocyte Colony-Stimulating Factor
por: Alshari O, et al.
Publicado: (2021) -
The importance of the prevention of treatment induced neutropenia in patients with malignant neoplasms of the head and neck
por: Editorial Board
Publicado: (2021) -
Interim results of a multicenter retrospective-prospective observational post-marketing study of Extimia® BIOCAD (INN: empegfilgrastim) to evaluate safety and efficacy in patients with lymphoproliferative diseases receiving cytotoxic therapy
por: Ekaterina S. Nesterova, et al.
Publicado: (2021)